SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-018802
Filing Date
2024-04-29
Accepted
2024-04-29 09:30:01
Documents
19
Period of Report
2024-04-26
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20240426.htm   iXBRL 8-K 34340
2 EX-99.1 libervantfdaapprovalprwi.htm EX-99.1 20301
6 libervantfdaapprovalprwi001.jpg GRAPHIC 274447
7 libervantfdaapprovalprwi002.jpg GRAPHIC 257841
8 libervantfdaapprovalprwi003.jpg GRAPHIC 241020
9 libervantfdaapprovalprwi004.jpg GRAPHIC 305046
10 libervantfdaapprovalprwi005.jpg GRAPHIC 211163
  Complete submission text file 0001628280-24-018802.txt   1966018

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20240426.xsd EX-101.SCH 1895
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20240426_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20240426_pre.xml EX-101.PRE 12504
22 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20240426_htm.xml XML 2719
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

IRS No.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 24887257
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)